AGL-2263 is an insulin receptor and insulin-like growth factor (IGF) receptor inhibitor.

Product information

CAS Number: 638213-98-6

Molecular Weight: 322.27

Formula: C17H10N2O5

Chemical Name: (2E)-2-[(E)-3,4-dihydroxybenzoyl]-3-(2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)prop-2-enenitrile

Smiles: N#C/C(=C\C1C=C2NC(=O)OC2=CC=1)/C(=O)C1=CC(O)=C(O)C=C1

InChiKey: IUGRBTCJEYEDIY-VZUCSPMQSA-N

InChi: InChI=1S/C17H10N2O5/c18-8-11(16(22)10-2-3-13(20)14(21)7-10)5-9-1-4-15-12(6-9)19-17(23)24-15/h1-7,20-21H,(H,19,23)/b11-5+

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 125 mg/mL (387.87 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

AGL-2263 (5 μM, for 1 h followed by insulin treatment for 24 h) inhibits IR and insulin could still induce phosphorylation of AKT and ERK1/2 after the IR inhibition.

Products are for research use only. Not for human use.